Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The inspection closed with the facility receiving an inspection classification of NAI
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Subscribe To Our Newsletter & Stay Updated
